المؤلفون: Dong, Meichen, Saini, Ritesh

المصدر: European Journal of Marketing, 2023, Vol. 57, Issue 5, pp. 1327-1351.

URL الوصول: http://www.emeraldinsight.com/doi/10.1108/EJM-11-2021-0841

المؤلفون: Wang, Jingguo¹ jwang@uta.edu, Dong, Meichen² meichen.dong@lamar.edu, Yang, Zhiyong³ yangz99@miamioh.edu, Li, Yuan⁴ yli213@utk.edu

المصدر: MIS Quarterly. Dec2023, Vol. 47 Issue 4, p1585-1614. 30p.

مصطلحات موضوعية: *INTERNET privacy, *SELF-disclosure, TEENAGERS, PARENTAL influences, ONLINE social networks, DATA privacy, PARENT-child communication, PARENT-teenager relationships

المؤلفون: Xia, Jiaxuan, Zhang, Shuya, Zhang, Ru, Wang, Anni, Zhu, Ying, Dong, Meichen, Ma, Shaojie, Hong, Chao, Liu, Shengyao, Wang, Dan, Wang, Jianxin

المساهمون: National Natural Science Foundation of China, the Development Project of Shanghai Peak Disciplines-Integrated Medicine

المصدر: Journal of Nanobiotechnology ; volume 20, issue 1 ; ISSN 1477-3155

الاتاحة: http://dx.doi.org/10.1186/s12951-022-01623-2
https://link.springer.com/content/pdf/10.1186/s12951-022-01623-2.pdf
https://link.springer.com/article/10.1186/s12951-022-01623-2/fulltext.html

المؤلفون: Sun, Jiajun, Dong, Meichen, Xiang, Xin, Zhang, Shubing, Wen, Doudou

المساهمون: National Natural Science Foundation of China

المصدر: Cancer Letters ; volume 585, page 216647 ; ISSN 0304-3835

الاتاحة: http://dx.doi.org/10.1016/j.canlet.2024.216647
https://api.elsevier.com/content/article/PII:S0304383524000417?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S0304383524000417?httpAccept=text/plain

المؤلفون: Yang, Rui, Wang, Wenzhe, Dong, Meichen, Roso, Kristen, Bao, Xuhui, Pirozzi, Christopher, Bigner, Darell, Yan, Hai, Ashley, David, Zhabotynsky, Vasyl, Zou, Fei, He, Yiping

المصدر: Neuro-Oncology ; volume 23, issue Supplement_1, page i5-i5 ; ISSN 1522-8517 1523-5866

الاتاحة: https://doi.org/10.1093/neuonc/noab090.017
http://academic.oup.com/neuro-oncology/article-pdf/23/Supplement_1/i5/38378152/noab090.017.pdf

المؤلفون: Sulkowski, Mark S., Moon, Juhi S., Sherman, Kenneth E., Morelli, Giuseppe, Darling, Jama M., Muir, Andrew J., Khalili, Mandana, Fishbein, Dawn A., Hinestrosa, Federico, Shiffman, Mitchell L., Di Bisceglie, Adrian, Rajender Reddy, K., Pearlman, Brian, Lok, Anna S., Fried, Michael W., Stewart, Paul W., Peter, Joy, Wadsworth, Summer, Kixmiller, Scott, Sloan, Anquenette, Vainorius, Monika, Horne, Patrick M., Michael, Larry, Dong, Meichen, Evon, Donna M., Segal, Jodi B., Nelson, David R.

المصدر: Hepatology ; volume 74, issue 6, page 2952-2964 ; ISSN 0270-9139 1527-3350

الاتاحة: http://dx.doi.org/10.1002/hep.32053
https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.32053
https://onlinelibrary.wiley.com/doi/full-xml/10.1002/hep.32053
https://journals.lww.com/10.1002/hep.32053

المؤلفون: Zhang, Shuya, Xia, Jiaxuan, Zhu, Ying, Dong, Meichen, Wang, Jianxin

المصدر: Molecules; Apr2024, Vol. 29 Issue 7, p1599, 13p

مصطلحات موضوعية: SALVIA miltiorrhiza, NEOVASCULARIZATION, REPERFUSION injury, CHINESE medicine, CELL migration, UMBILICAL veins, CELL survival, NANOMEDICINE

المؤلفون: Dong, Meichen, Thennavan, Aatish, Urrutia, Eugene, Li, Yun, Perou, Charles M, Zou, Fei, Jiang, Yuchao

المساهمون: National Institutes of Health, National Cancer Institute, Breast Cancer Research Foundation, UNC Lineberger Comprehensive Cancer Center, UNC Computational Medicine Program

المصدر: Briefings in Bioinformatics ; volume 22, issue 1, page 416-427 ; ISSN 1477-4054

الاتاحة: http://dx.doi.org/10.1093/bib/bbz166
http://academic.oup.com/bib/article-pdf/22/1/416/35934954/bbz166.pdf

المؤلفون: ZHANG Tao, WEI Yun, DONG Meichen, ZHANG Huanliang, LI Lanlan, HOU Tianchi, FENG Yan

المصدر: Electroplating & Finishing; 12/15/2023, Vol. 42 Issue 24, p67-74, 8p

المؤلفون: Dong, Meichen, Saini, Ritesh

المصدر: Journal of Business Research ; volume 166, page 114126 ; ISSN 0148-2963

الاتاحة: http://dx.doi.org/10.1016/j.jbusres.2023.114126
https://api.elsevier.com/content/article/PII:S014829632300485X?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S014829632300485X?httpAccept=text/plain

المؤلفون: Kuang, Yunmei, Dong, Meichen

المصدر: Developments in Marketing Science: Proceedings of the Academy of Marketing Science ; From Micro to Macro: Dealing with Uncertainties in the Global Marketplace ; page 467-468 ; ISSN 2363-6165 2363-6173 ; ISBN 9783030898823 9783030898830

الاتاحة: http://dx.doi.org/10.1007/978-3-030-89883-0_118
https://link.springer.com/content/pdf/10.1007/978-3-030-89883-0_118

المؤلفون: Dong, Meichen, Kuang, Yunmei, Chen, Wei

المصدر: Celebrating the Past and Future of Marketing and Discovery with Social Impact ; Developments in Marketing Science: Proceedings of the Academy of Marketing Science ; page 367-368 ; ISSN 2363-6165 2363-6173 ; ISBN 9783030953454 9783030953461

الاتاحة: http://dx.doi.org/10.1007/978-3-030-95346-1_113
https://link.springer.com/content/pdf/10.1007/978-3-030-95346-1_113

المؤلفون: DONG Meichen, YU Juanjuan, QIN Zhi, DAI Shaojun

المصدر: Journal of Shanghai Normal University (Natural Sciences), Vol 47, Iss 6, Pp 639-646 (2018)

مصطلحات موضوعية: plant, chloroplast, S-nitrosylation, proteomics, Science (General), Q1-390

Relation: http://qktg.shnu.edu.cn/zrb/shsfqkszrb/ch/reader/view_abstract.aspx?file_no=20180601; https://doaj.org/toc/1000-5137; https://doaj.org/article/e394195f252c4e5085bc94d21eb44197

الاتاحة: https://doi.org/10.3969/J.ISSN.1000-5137.2018.06.001
https://doaj.org/article/e394195f252c4e5085bc94d21eb44197

المؤلفون: Dong, Meichen¹ (AUTHOR), He, Yiping² (AUTHOR), Jiang, Yuchao^1,3 (AUTHOR), Zou, Fei^1,3 (AUTHOR) feizou@email.unc.edu

المصدر: Biometrics. Jun2023, Vol. 79 Issue 2, p915-925. 11p.

مصطلحات موضوعية: *GENE expression, *LOW-rank matrices, *GENE regulatory networks

المؤلفون: Evon, Donna M., Dong, Meichen, Reeve, Bryce B., Peter, Joy, Michael, Larry, Lok, Anna S., Nelson, David R., Stewart, Paul W.

مصطلحات موضوعية: sustained virological response, comparative effectiveness, direct acting antiviral, instrument, patient‐reported outcomes, survey, Oncology and Hematology, Health Sciences

وصف الملف: application/pdf

Relation: Evon, Donna M.; Dong, Meichen; Reeve, Bryce B.; Peter, Joy; Michael, Larry; Lok, Anna S.; Nelson, David R.; Stewart, Paul W. (2022). "Sustainable and equivalent improvements in symptoms and functional well‐being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial." Journal of Viral Hepatitis (9): 795-806.; https://hdl.handle.net/2027.42/174829; Journal of Viral Hepatitis; Liu GF, Lu K, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? Stat Med. 2009; 28: 2509 ‐ 2530.; Gordon SC, Muir AJ, Lim JK, et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV‐TARGET. J Hepatol. 2015; 62: 286 ‐ 293.; Kixmiller S, Sloan AP, Wadsworth S, et al. Experiences of an HCV Patient engagement group: a seven‐year journey. Res Involv Engagem. 2021; 7: 7.; Cella D, Riley W, Stone A, et al. The Patient‐Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self‐reported health outcome item banks: 2005–2008. J Clin Epidemiol. 2010; 63: 1179 ‐ 1194.; Reeve BB, Hays RD, Bjorner JB, et al. Psychometric evaluation and calibration of health‐related quality of life item banks: plans for the Patient‐Reported Outcomes Measurement Information System (PROMIS). Med Care 2007; 45: S22 ‐ S31.; NIH PROMIS® Reference Populations. [Internet]. https://www.healthmeasures.net/score‐and‐interpret/interpret‐scores/promis/reference‐populations. Accessed September 17, 2021.; Evon DM, Amador J, Stewart P, et al. Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. Aliment Pharmacol Ther. 2018; 47: 1001 ‐ 1011.; Lee AC, Driban JB, Price LL, Harvey WF, Rodday AM, Wang C. Responsiveness and minimally important differences for 4 patient‐reported outcomes measurement information system short forms: Physical function, pain interference, depression, and anxiety in knee osteoarthritis. J Pain. 2017; 18: 1096 ‐ 1110.; Khanna D, Hays RD, Shreiner AB, et al. Responsiveness to change and minimally important differences of the patient‐reported outcomes measurement information system gastrointestinal symptoms scales. Dig Dis Sci. 2017; 62: 1186 ‐ 1192.; Amtmann D, Kim J, Chung H, Askew RL, Park R, Cook KF. Minimally important differences for patient reported outcomes measurement information system pain interference for individuals with back pain. J Pain Res. 2016; 9: 251 ‐ 255.; Kroenke K, Yu Z, Wu J, Kean J, Monahan PO. Operating characteristics of PROMIS four‐item depression and anxiety scales in primary care patients with chronic pain. Pain Med. 2014; 15: 1892 ‐ 1901.; Anderson RT, Baran RW, Dietz B, Kallwitz E, Erickson P, Revicki DA. Development and initial psychometric evaluation of the hepatitis C virus‐patient‐reported outcomes (HCV‐PRO) instrument. Qual Life Res. 2014; 23: 561 ‐ 570.; Anderson RT, Baran RW, Erickson P, Revicki DA, Dietz B, Gooch K. Psychometric evaluation of the hepatitis C virus patient‐reported outcomes (HCV‐PRO) instrument: validity, responsiveness, and identification of the minimally important difference in a phase 2 clinical trial. Qual Life Res. 2014; 23: 877 ‐ 886.; Lu K. On efficiency of constrained longitudinal data analysis versus longitudinal analysis of covariance. Biometrics. 2010; 66: 891 ‐ 896.; Liang K, Zeger S. Longitudinal data analysis of continuous and discrete responses for pre–post designs. Sankhyā Ind J Stat (Series B). 2000; 62: 134 ‐ 148.; Marcellin F, Roux P, Protopopescu C, Duracinsky M, Spire B, Carrieri MP. Patient‐reported outcomes with direct‐acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Rev Gastroenterol Hepatol. 2017; 11: 259 ‐ 268.; Evon DM, Kim HP, Edwards A, et al. "If I get cured, my whole quality of life will change": patients’ anticipated and actualized benefits following cure from chronic hepatitis C. Dig Dis Sci. 2021; 67: 100 ‐ 120.; Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of health‐related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol. 2015; 63: 337 ‐ 345.; Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourliere M. The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016; 36: 42 ‐ 48.; Serper M, Evon DM, Amador J, et al. Patient‐reported outcomes 12 months after hepatitis C treatment with direct‐acting antivirals: results from the PROP UP study. Liver Int. 2021; 41: 692 ‐ 704.; Schulte B, Schmidt CS, Manthey J, et al. Clinical and patient‐reported outcomes of direct‐acting antivirals for the treatment of chronic hepatitis C among patients on opioid agonist treatment: a real‐world prospective cohort study. Open Forum Infect Dis. 2020; 7: ofaa317.; Fagundes RN, Ferreira L, Pace FHL. Health‐related quality of life and fatigue in patients with chronic hepatitis C with therapy with direct‐acting antivirals agents interferon‐free. PLoS One. 2020; 15: e0237005.; Karimi‐Sari H, Hosseini MA, Nikjoo N, Bagheri Baghdasht MS, Alavian SM. Patient‐reported outcomes of sleep, mood and quality of life after treatment of chronic hepatitis C infection using direct‐acting antiviral agents. Clin Microbiol Infect 2020; 26: 1093.e5‐.e8.; Ichikawa T, Miyaaki H, Miuma S, et al. Direct‐acting antivirals improved the quality of life, ameliorated disease‐related symptoms, and augmented muscle volume three years later in patients with hepatitis C virus. Intern Med. 2020; 59: 2653 ‐ 2660.; Goutzamanis S, Horyniak D, Doyle JS, Hellard M, Higgs P. Perceived physical health outcomes of direct‐acting antiviral treatment for hepatitis C: a qualitative study. Harm Reduct J. 2021; 18: 73.; O’Sullivan M, Jones AM, Gage H, et al. ITTREAT (Integrated Community Test ‐ Stage ‐ TREAT) Hepatitis C service for people who use drugs: Real‐world outcomes. Liver Int. 2020; 40: 1021 ‐ 1031.; Tsui JI, Williams EC, Green PK, Berry K, Su F, Ioannou GN. Alcohol use and hepatitis C virus treatment outcomes among patients receiving direct antiviral agents. Drug Alcohol Depend. 2016; 169: 101 ‐ 109.; Grebely J, Dalgard O, Conway B, et al. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open‐label, single‐arm, phase 4, multicentre trial. Lancet Gastroenterol Hepatol. 2018; 3: 153 ‐ 161.; Recommendations for testing, managing, and treating hepatitis C. January 2022. Accessed January 17, 2022. http://www.hcvguidelines.org; Lang CA, Conrad S, Garrett L, et al. Symptom prevalence and clustering of symptoms in people living with chronic hepatitis C infection. J Pain Symptom Manage. 2006; 31: 335 ‐ 344.; Jacobson IM, Cacoub P, Dal Maso L, Harrison SA, Younossi ZM. Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol. 2010; 8: 1017 ‐ 1029.; Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: a meta‐analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016; 150: 1599 ‐ 1608.; Kleefeld F, Heller S, Ingiliz P, et al. Interferon‐free therapy in hepatitis C virus (HCV) monoinfected and HCV/HIV coinfected patients: effect on cognitive function, fatigue, and mental health. J Neurovirol. 2018; 24: 557 ‐ 569.; McCarthy M, Ortega MR. Neurological complications of hepatitis C infection. Curr Neurol Neurosci Rep. 2012; 12: 642 ‐ 654.; Grover VP, Pavese N, Koh SB, et al. Cerebral microglial activation in patients with hepatitis C: in vivo evidence of neuroinflammation. J Viral Hepat. 2012; 19: e89 ‐ e96.; Burgel B, Friesland M, Koch A, et al. Hepatitis C virus enters human peripheral neuroblastoma cells – evidence for extra‐hepatic cells sustaining hepatitis C virus penetration. J Viral Hepat. 2011; 18: 562 ‐ 570.; Tassi A, Gitto S, Piras C, et al. Cognitive, neurological and psychiatric disorders occurring in hepatitis C virus infection. Minerva Med. 2021; 112: 238 ‐ 245.; Monaco S, Mariotto S, Ferrari S, et al. Hepatitis C virus‐associated neurocognitive and neuropsychiatric disorders: advances in 2015. World J Gastroenterol. 2015; 21: 11974 ‐ 11983.; Tagliapietra M, Monaco S. Neuroimaging findings in chronic hepatitis C virus infection: Correlation with neurocognitive and neuropsychiatric manifestations. Int J Mol Sci. 2020; 21: 2478.; Ghany MG, Morgan TR. Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases‐Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Hepatology. 2020; 71: 686 ‐ 721.; Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT‐450/r‐ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370: 1594 ‐ 1603.; Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir‐Elbasvir combination therapy for treatment‐naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015; 163: 1 ‐ 13.; Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir‐based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014; 12: 1349 ‐ 1359.e13.; Evon DM, Sarkar S, Amador J, et al. Patient‐reported symptoms during and after direct‐acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019; 71: 486 ‐ 497.; Sung JC, Bosh C, Wyatt B, et al. Hepatitis C cure improved patient‐reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center. J Viral Hepat. 2020; 27: 350 ‐ 359.; Sulkowski MS, Moon J, Sherman K, et al. A pragmatic, randomized controlled trial of oral antivirals for the treatment of chronic hepatitis C: the prioritize study. Hepatology. 2021; 74: 2952 ‐ 2964.; Evon DM, Golin CE, Stoica T, et al. What’s important to the patient? Informational needs of patients making decisions about hepatitis C treatment. Patient. 2017; 10: 335 ‐ 344.

الاتاحة: https://hdl.handle.net/2027.42/174829
https://doi.org/10.1111/jvh.13716

المؤلفون: Xia, Jiaxuan, Zhang, Shuya, Zhang, Ru, Wang, Anni, Zhu, Ying, Dong, Meichen, Ma, Shaojie, Hong, Chao, Liu, Shengyao, Wang, Dan, Wang, Jianxin

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::106ac6e977d24cdaac508b481b3f1dd1

المؤلفون: Niu, Yuyao, Lu, Zhengyang, Dong, Meichen, Jin, Zhou, Liu, Weifeng, Tan, Guangming

المساهمون: Science Challenge Project, National Natural Science Foundation of China

المصدر: 2021 IEEE International Parallel and Distributed Processing Symposium (IPDPS)

الاتاحة: http://dx.doi.org/10.1109/ipdps49936.2021.00016
http://xplorestaging.ieee.org/ielx7/9458946/9458962/09460505.pdf?arnumber=9460505

المؤلفون: Li, Zhongwei, Hou, Pingfu, Fan, Dongmei, Dong, Meichen, Ma, Musong, Li, Hongyuan, Yao, Ruosi, Li, Yuxin, Wang, Guannan, Geng, Pengyu, Mihretab, Adhanom, Liu, Dongxu, Zhang, Yu, Huang, Baiqu, Lu, Jun

المصدر: Cell Death & Differentiation ; volume 24, issue 1, page 59-71 ; ISSN 1350-9047 1476-5403

الاتاحة: http://dx.doi.org/10.1038/cdd.2016.95
http://www.nature.com/articles/cdd201695.pdf
http://www.nature.com/articles/cdd201695

المؤلفون: Dong, Meichen, Zhang, Yingying

المصدر: Advances in Intelligent Systems Research ; Proceedings of the 2013 International Conference on Advances in Social Science, Humanities, and Management ; ISSN 1951-6851

الاتاحة: http://dx.doi.org/10.2991/asshm-13.2013.30

المؤلفون: Berman, Barry, Dong, Meichen

المصدر: The International Review of Retail, Distribution and Consumer Research ; volume 26, issue 1, page 95-111 ; ISSN 0959-3969 1466-4402

الاتاحة: http://dx.doi.org/10.1080/09593969.2015.1058837
http://www.tandfonline.com/doi/pdf/10.1080/09593969.2015.1058837